Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 20, 2024 /PRNewswire/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84% increase in cancer cases and a 93% rise in cancer deaths among men by 2050. According to Our World in Data, cancer has overtaken cardiovascular diseases as the leading cause of death in several wealthy nations. Despite warnings from the American Cancer Society, which found that 44% of cancer deaths in U.S. adults are linked to lifestyle factors, troubling trends continue. Another study revealed that even light drinking is associated with an increase in cancer death

- Transaction Will Maximize the Access and Uptake of COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - G1 Stockholders to Receive U.S. $7.15 Per Share in Cash - HOLBAEK, Denmark and RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, and G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company focused on delivering next-generation therapies that improve the lives of those affected by cancer, today announced that Pharmacosmos A/S has successfully completed the previously announce

HOLBAEK, Denmark and RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, and G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company focused on delivering next-generation therapies that improve the lives of those affected by cancer, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") relating to Pharmacosmos' previously announced acquisition of G1 Therapeutics. The expiration of the waiting period occurred at 11:59 p.m. EST on September 4, 2

JP Morgan upgraded G1 Therapeutics from Underweight to Neutral and set a new price target of $10.00 from $7.00 previously

Needham reiterated coverage of G1 Therapeutics with a rating of Buy and set a new price target of $31.00 from $32.00 previously

JP Morgan downgraded G1 Therapeutics from Neutral to Underweight and set a new price target of $19.00 from $20.00 previously

4 - G1 Therapeutics, Inc. (0001560241) (Issuer)

4 - G1 Therapeutics, Inc. (0001560241) (Issuer)

4 - G1 Therapeutics, Inc. (0001560241) (Issuer)

15-12G - G1 Therapeutics, Inc. (0001560241) (Filer)

S-8 POS - G1 Therapeutics, Inc. (0001560241) (Filer)

S-8 POS - G1 Therapeutics, Inc. (0001560241) (Filer)

Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB DIHYDROCHLORIDE has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity

Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity

For Immediate Release: February 12, 2021 Today, the U.S. Food and Drug Administration approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer. Cosela may help protect bone marrow cells from damage caused by chemotherapy by inhi

RESEARCH TRIANGLE PARK, N.C., May 22, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the appointment of Monica Thomas as its General Counsel and Chief Compliance Officer. Mrs. Thomas replaces Stillman Hanson who departed the Company in May 2023. "G1 is in the midst of an important period in our evolution, as we evolve our commercial and clinical capabilities to maximize the future value of COSELA® (trilaciclib) and ensure that all appropriate patients may have access to this important drug," said Jack Bailey, Chief Executive Officer of G1 Therapeutics. "As we do so, it is essential that we maintain our fundamental focus o

RESEARCH TRIANGLE PARK, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the appointment of Norman E. "Ned" Sharpless, M.D., to its Board of Directors. For nearly 30 years, Dr. Sharpless has been committed to the fight against cancer, including serving as one of the scientific founders of G1 in 2008. He is an accomplished oncologist and seasoned public servant who has treated cancer patients, investigated the biologic basis of cancer, and has led academic institutions and government agencies, including most recently serving as Director of the National Cancer Institute (NCI) at the National Institutes of Health

RESEARCH TRIANGLE PARK, N.C., June 28, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the appointment of Jacks Lee to its Board of Directors. For more than 30 years, Mr. Lee has developed extensive experience in manufacturing and supply chain management in the life sciences industry. Mr. Lee currently serves as Senior Vice President – Manufacturing & Supply of Merck & Co., Inc., a global premier research-intensive biopharmaceutical health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. "G1's Board of Directors comprises ex

- Entered into Definitive Merger Agreement to be Acquired by Pharmacosmos; Transaction Expected to Close in Late Third Quarter 2024 - - Achieved $15.8 Million in Net Revenue from Sales of COSELA® (trilaciclib) - - Drove Double Digit Quarter-Over-Quarter Growth in COSELA Vial Volume and Net Revenue - - Reaffirmed 2024 Net COSELA Revenue Guidance of Between $60 and $70 Million - - Due to the Pending Transaction with Pharmacosmos, G1 will Not Host a Conference Call and Webcast to Discuss the Second Quarter Financial Results and Business Update - RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today

- Business Combination Expected to Provide Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Optimal Access to G1's COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - Pharmacosmos' Significant Resources and Expertise in Hematology and Supportive Care to Maximize Availability of COSELA for Patients with ES-SCLC - - Transaction Expands and Strengthens Pharmacosmos' Global Commercial Portfolio - - G1's Shareholders to Receive U.S. $7.15 per Share in Cash for a Total Equity Value of Approximately $405 Million - RESEARCH TRIANGLE PARK, N.C. and HOLBAEK, Denmark, Aug. 07, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASD

RESEARCH TRIANGLE PARK, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the second quarter of 2024 on Thursday August 8, 2024, at 8:30 a.m. ET. To register for the event and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended that you join 10 minutes prior to the start of the event. A live and archived webcast will be available on the Events & Presentations page of the company's website: www.g1therapeutics.com. The webcast will be ar

SC 13G - G1 Therapeutics, Inc. (0001560241) (Subject)

SC 13D/A - G1 Therapeutics, Inc. (0001560241) (Subject)

SC 13G/A - G1 Therapeutics, Inc. (0001560241) (Subject)